参考文献/References:
[1] Stoekenbroek RM,Lambert G,Cariou B,et al. Inhibiting PCSK9-biology beyond LDL control[J]. Nat Rev Endocrinol,2018,15(1):52-62.
[2] Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[3] Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[4] Kastelein JJ,Nissen SE,Rader DJ,et al. Safety and efficacy of LY3015014,a monoclonal antibody to proprotein convertase subtilisin/kexin type 9(PCSK9):a randomized,placebo-controlled Phase 2 study[J]. Eur Heart J,2016,37(17):1360-1369.
[5] Baruch A,Mosesova S,Davis JD,et al. Effects of RG7652,a monoclonal antibody against PCSK9,on LDL-C,LDL-C Subfractions,and Inflammatory biomarkers in patients at high risk of or with established coronary heart disease(from the Phase 2 EQUATOR Study) [J]. Am J Cardiol,2017,119(10):1576-1583.
[6] Crossey E,Amar MJA,Sampson M,et al. A cholesterol-lowering VLP vaccine that targets PCSK9[J]. Vaccine,2015,33(43):5747-5755.
[7] Landlinger C,Pouwer MG,Juno C,et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation,and atherosclerosis in APOE*3Leiden.CETP mice[J]. Eur Heart J,2017,38(32):2499-2507.
[8] Mitchell T,Chao G,Sitkoff D,et al. Pharmacologic profile of the Adnectin BMS-962476,a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering[J]. J Pharmacol Exp Ther,2014,350(2):412-424.
[9] Zhang Y,Eigenbrot C,Zhou L,et al. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor[J]. J Biol Chem,2014,289(2):942-955.
[10] Schroeder CI,Swedberg JE,Withka JM,et al. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro[J]. Chem Biol,2014,21(2):284-294.
[11] Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
[12] Miyosawa K,Watanabe Y,Murakami K,et al. New CETP inhibitor K-312 reduces PCSK9 expression:a potential effect on LDL cholesterol metabolism[J]. Am J Physiol Endocrinol Metab,2015,309(2):E177-E190.
[13] El-Seweidy MM,Sarhan Amin R,Husseini Atteia H,et al. Dyslipidemia induced inflammatory status,platelet activation and endothelial dysfunction in rabbits:protective role of 10-Dehydrogingerdione [J]. Biomed Pharmacother,2019,110:456-464.
[14] Li S,Zhu CG,Guo YL,et al. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease[J]. J Atheroscler Thromb,2015,22(1):76-84.
[15] Pastori D,Nocella C,Farcomeni A,et al. Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation[J]. J Am Coll Cardiol,2017,70(12):1455-1462.
[16] Navarese EP,Kolodziejczak M,Winter MP,et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor:the PCSK9-REACT study[J]. Int J Cardiol,2017,227:644-649.
[17] Camera M,Rossetti L,Barbieri SS,et al. PCSK9 as a positive modulator of platelet activation[J]. J Am Coll Cardiol,2018,71(8):952-954.
[18] Hu D,Yang Y,Peng DQ. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9(PCSK9) in statin-naive patients with coronary artery disease[J]. Int J Cardiol,2017,227:61-65.
[19] Almontashiri NA,Vilmundarson RO,Ghasemzadeh N,et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies[J]. PLoS One,2014,9(9):e106294.
[20] Zhang Y,Liu J,Li S,et al. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat[J]. BMC Cardiovasc Disord,2014,14:192.
[21] Barale C,Bonomo K,Frascaroli C,et al. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody:a 12-month follow-up[J]. Nutr Metab Cardiovasc Dis,2020,30(2):282-291.
[22] Liu Z,Xiang Q,Zhao X,et al. Candidate gene and pathway analyses identifying genetic variations associated with prasugrel pharmacokinetics and pharmacodynamics[J]. Thromb Res,2019,173:27-34.
[23] Rossetti L,Ferri N,Marchiano S,et al. PCSK9 beyond its role in cholesterol homeostasis:co?activator of platelet function[J]. Eur Heart J,2017,38(suppl):446-447.
[24] Momtazi-Borojeni AA,Sabouri-Rad S,Gotto A M,et al. PCSK9 and inflammation:a review of experimental and clinical evidence[J]. Eur Heart J Cardiovasc Pharmacother,2019,5(4):237-245.
[25] Cammisotto V,Pastori D,Nocella C,et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation[J]. Antioxidants(Basel),2020,9(4):296.
[26] Paciullo F,Momi S,Gresele P. PCSK9 in haemostasis and thrombosis:possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention[J]. Thromb Haemost,2019,119(3):359-367.
[27] Wang N,Tall AR. Cholesterol in platelet biogenesis and activation[J]. Blood,2016,127(16):1949-1953.
[28] Panes O,Gonzalez C,Hidalgo P,et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin,but not by atorvastatin [J].Atherosclerosis,2017,257:164-171.
[29] Akkerman JW. From low-density lipoprotein to platelet activation[J]. Int J Biochem Cell Biol,2008,40(11):2374-2378.
[30] Magwenzi S,Woodward C,Wraith K S,et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade[J]. Blood,2015,125(17):2693-2703.
[31] Biswas S,Zimman A,Gao D,et al. TLR2 plays a key role in platelet hyperreactivity and accelerated thrombosis associated with hyperlipidemia[J]. Circ Res,2017,121(8):951-962.
[32] Xu S,Ogura S,Chen J,et al. LOX-1 in atherosclerosis:biological functions and pharmacological modifiers[J]. Cell Mol Life Sci,2013,70(16):2859-2872.
[33] Carnevale R,Bartimoccia S,Nocella C,et al. LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism[J]. Atherosclerosis,2014,237(1):108-116.
[34] Stellos K,Sauter R,Fahrleitner M,et al. Binding of oxidized low-density lipoprotein on circulating platelets is increased in patients with acute coronary syndromes and induces platelet adhesion to vascular wall in vivo—brief report[J]. Arterioscler Thromb Vasc Biol,2012,32(8):2017-2020.
[35] Ding Z,Liu S,Wang X,et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues[J]. Cardiovasc Res,2015,107(4):556-567.
[36] Biswas S,Xin L,Panigrahi S,et al. Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE-/- mice and activate platelets via TLR2[J]. Blood,2016,127(21):2618-2629.
[37] Calkin AC,Drew BG,Ono A,et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux[J]. Circulation,2009,120(21):2095-2104.
[38] Riddell DR,Graham A,Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease[J]. J Biol Chem,1997,272(1):89-95.
[39] Valiyaveettil M,Kar N,Ashraf MZ, et al. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI[J]. Blood,2008,111(4):1962-1971.
相似文献/References:
[1]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(1):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[2]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(1):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[3]石惠薇 热娜提·肉孜 刘硕霖 吴娜琼.高脂蛋白a血症的相关治疗进展[J].心血管病学进展,2021,(4):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
SHI Huiwei,Rinat·Rozi,LIU Shuolin,et al.Lipoprotein(a)-lowering Therapy[J].Advances in Cardiovascular Diseases,2021,(1):297.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.003]
[4]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(1):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
[5]殷人麟 尤华 郑林.前蛋白转化酶枯草溶菌素9抑制剂与冠状动脉粥样硬化斑块逆转的研究进展[J].心血管病学进展,2022,(8):710.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.011]
YIN Renlin,YOU hua,Zheng Lin?/html>.PCSK9 Inhibitors in?nhibiting Coronary Atherosclerotic Plaque[J].Advances in Cardiovascular Diseases,2022,(1):710.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.011]
[6]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(1):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]